Drug Profile


Alternative Names: HBI-3000; Sulcardine sulphate

Latest Information Update: 07 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu Furui Pharmaceuticals; Shanghai Institute of Materia Medica
  • Developer HUYA Bioscience International; Jiangsu Furui Pharmaceuticals
  • Class Antiarrhythmics
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Arrhythmias

Highest Development Phases

  • Preclinical Arrhythmias

Most Recent Events

  • 07 Jan 2016 Preclinical trials in Arrhythmias in USA (IV)
  • 05 Feb 2013 Phase-II development is ongoing in China
  • 05 Feb 2013 No development reported - Phase-II for Arrhythmias in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top